600+ sources. One page. See who else covered it.
Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
The lender will pay shareholders a total of Sh9.64 billion, up from the Sh2 per share paid in the same period last year.
Costs remain elevated for consumers, however inflation is showing some signs of easing, economists say.
The fund returned 11.5% in the second quarter—the best result since 2020.
Tata Consultancy Services, the group’s largest listed entity with a market cap of ₹8.50 lakh crore, bore the sharpest absolute brunt, closing down 3.93 per cent at ₹2,349.70
BNY notes Crude Oil prices remain elevated as doubts over a U.S.–Iran deal heighten supply concerns. The IEA reports global Oil markets tightened further in July, with demand, supply, refining runs…
The Japanese Yen trims its gains against the US Dollar (USD) on Wednesday as in-line US CPI data fails to trigger a significant move.